Portfolio Companies :Nuvaira
Gary RieschelCo-Founder and Partner
Gary Rieschel has over 35 years of successful operating and investing experience as a senior executive, entrepreneur, investor, and global business strategist. Gary has held executive positions at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Over the last 20 years as a venture capitalist, he led investments in 13 companies in the US and China which grew to over $1B USD in market capitalization. Gary aided in the creation of the venture capital industry in China through sponsoring and founding several of China’s leading VC firms including Softbank China Ventures, SAIF Partners (2001), Ceyuan Ventures (2004), and Qiming Venture Partners (2006). He is Founding Managing Partner of Qiming, one of China’s preeminent VC firms with over $4.3B under management. In 2016, Gary returned to the States after 12 years in China to launch Qiming’s first operation in the US. Qiming US has over $300M USD under management invested in cutting edge healthcare investments. Gary serves on the board of Nuvaira and remains on Qiming’s Executive and Investment Committees. He also serves on the board of Lanzatech, a leading environmental biotech company.
Gary is well regarded as a mentor to entrepreneurs, founders, and other venture capitalists. He is on the board of many preeminent environmental organizations including The Nature Conservancy (Montana), PERC (Free Market Environmentalism), the Climate Leadership Council, the Asia Society (Advisor), and helped introduce the Rocky Mountain Institute into China. Gary also serves on the board of the US Olympic Foundation and is a permanent member of the Council on Foreign Relations.
Gary holds a BA in Biology from Reed College in Portland, OR where he is a long time Trustee, and an MBA from the Harvard Business School. He lived in Japan for five years in the late 1980s and in Shanghai from 2005 through 2016. He now resides in Seattle, WA.
Mark McDadeCo-Founder and Partner
Mark McDade co-founded Qiming Venture Partners USA in January 2017 and has over 30 years of successful operating experience in private and public healthcare and life sciences companies. Prior to Qiming, Mark was Executive Vice President and Chief Operating Officer (COO) of UCB, the Brussels, Belgium-based global biopharma.
Previously, Mark served as Chief Executive Officer (CEO) and a director of PDL Biopharma and led Signature Bioscience as its CEO. Mark also was a founder and director of Corixa Corporation, where he served as COO and then as President & COO. Earlier in his career, Mark was COO of Boehringer Mannheim Therapeutics, the biopharmaceutical division of Corange. Prior to that, he held several positions of increasing responsibility at Sandoz Ltd. (now Novartis), including business development, product management, and general management.
Mark is on the boards of several of Qiming’s portfolio companies, notably serving as chairman of the board of Icosavax (Nasdaq: ICVX). He previously served as chairman of the board of Aimmune Therapeutics until its acquisition by Nestlé Health Sciences and as a director of Dermira until its acquisition by Eli Lilly & Company. He also serves as a director of Mumbai-based Lupin Ltd. and as a trustee of the National Marine Sanctuary Foundation.
Mark received a B.A. from Dartmouth College and an M.B.A. from the Harvard Business School.
Anna French, DPhil joined Qiming Venture Partners USA in 2017 and is based in Cambridge, MA. Prior to joining the Qiming team, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization.
Anna earned a D.Phil from the University of Oxford, UK where her research focused on hematological differentiation of human induced pluripotent stem (iPS) cells. She has over 20 publications in the field of stem cell research.
Anna currently serves on the boards of WindMIL Therapeutics, Jasper Therapeutics, Umoja Biopharma, Auron Therapeutics and Cardialen. She is a board observer with Talaris Therapeutics and PlateletBio.
Colin Walsh, Ph.D. joined Qiming Venture Partners USA in April 2019 and is based in South San Francisco, CA. He currently serves on the boards of Elevation Oncology, Korro Bio and Element Science and is a board observer of Amphivena Therapeutics, Icosavax, and Ventyx Biosciences.
Before joining Qiming in 2019, Colin was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to ND Capital, he held a number of roles as an early employee at Precision NanoSystems, a 5AM Ventures backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations.
Colin earned a Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering where he worked on novel delivery systems for RNA therapeutics as an NSF Graduate Research Fellow. He holds a Management of Technology certificate from the UC Berkeley Haas School of Business, and a dual BS with Honors in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst.
Colin currently serves on the business advisory board for the Harvard Medical School Initiative for RNA Medicine. He is also an advisor to the Stanford SPARK program and the UCSF Catalyst program where he provides mentorship and support to student- and faculty-led translational research projects.
Bruce BeutelVenture Partner
Bruce Beutel, Ph.D. is a Venture Partner at Qiming Venture Partners USA, based in the Cambridge, MA office. Prior to joining Qiming in October of 2021, Bruce had nearly 30 years of leadership experience in drug discovery and business development roles in biotech and pharmaceutical companies.
Most recently, from 2018-2021, Bruce was Chief Operating Officer and Chief Business & Strategy Officer at Dewpoint Therapeutics, where he was central to all aspects of building the business, establishing the platform, and negotiating partnerships with Bayer, Merck, and Pfizer from pre-seed through series B and the hiring of the first hundred employees.
From 2018-2020, Bruce was also an Entrepreneur in Residence at the Polaris Innovation Fund, assisting in sourcing, due diligence, and company creation.
From 2014-2018 Bruce focused on Business Development as Chief Business Officer at SQZ Biotechnologies, and as Executive Director, Business Development at Merck, after making the move from R&D to business development. Prior to this he had served more than twenty years leading drug discovery research teams in roles including Executive Director, Pharmacology at Merck, Chief Scientific Officer at Znomics, Senior Director at Abbott Laboratories, and Group Head at PharmaGenics. His work in R&D encompassed a broad range of disease areas and drug discovery technologies, resulting in the invention of novel drug discovery technologies and several first-in-class molecules entering clinical trials.
Bruce has over 30 peer reviewed publications and 7 issued patents. He received his B.A. in Biology from the University of Chicago and his Ph.D. in Molecular Biology from the University of Wisconsin-Madison in the lab of M. Thomas Record, Jr.
Will McConnellVice President
Will McConnell joined the Qiming team in early 2020 and is based in the Cambridge, MA office.
Prior to joining the firm he was an analyst at Biomatics Capital, an early stage life sciences-focused venture fund, with responsibilities in pipeline evaluation, diligence activities, and portfolio support. Prior to Biomatics Will worked at L.E.K. Consulting, where he primarily focused on business development strategy and transactional support for a range of healthcare clients (discovery / clinical-stage biotechs to large biopharmas).
Will holds a B.A. from Dartmouth College in Biology and Computer Science, where he was also a member of the Division I basketball team. In his free time the San Francisco-Bay Area native enjoys traveling and playing pick-up basketball.
Phil DiGiacomoVice President
Phil DiGiacomo joined the Qiming Venture Partners USA team in July 2020 as an Associate based in the South San Francisco, CA office.
Prior to joining Qiming, Phil spent several years as a part-time associate at ND Capital while completing his PhD. He focused on the sourcing and diligence of early-stage life science companies, as well as portfolio support.
Phil completed his PhD in Bioengineering at Stanford University where his research focused on the discovery and development of novel biomarkers and therapeutic targets for neuroinflammatory diseases as a SPARK Translational Research Fellow and Training in Imaging and Instrumentation Fellow. He holds a Master’s of Science in Medicine from the Stanford University School of Medicine and a Bachelor’s with Distinction in Mathematics, Cognitive Science, and Biomedical Engineering from the University of Virginia.
Artavazd Arumov, PhD joined the Qiming Ventures Partners USA team in May 2021 and is based in the Cambridge, MA office.
Prior to joining Qiming, Artavazd held numerous roles across the life sciences. He led business development and therapeutic strategy for early-stage biotech Redesign Science. Prior to Redesign Science, he completed doctorate training at the University of Miami’s Miller School of Medicine. He also spent time in clinical research at Memorial Sloan Kettering Cancer Center, where he was responsible for the end-to-end management and operations of a portfolio of breast cancer sponsored and investigator initiated phase I/II clinical trials.
Artavazd completed his PhD in Cancer Biology at the University of Miami Miller School of Medicine’s Sylvester Comprehensive Cancer Center. His research focused on the development and advancement of novel precision therapeutics for use in lymphoma and the study of fundamental drug resistance mechanisms. He currently serves as an entrepreneur in residence for U Innovation’s Coulter Center for Translational Research. He also holds a B.S. in Biology from Brooklyn’s St. Francis College.
Franklin BergerSenior Advisor
Franklin currently serves on the board of six public biotechnology companies: Five Prime Therapeutics (NASDAQ: FPRX), Bellus Health (NASDAQ: BLU), ESSA Pharma (NASDAQ: EPIX), Proteostasis (NASDAQ:PTI), Tocagen (NASDAQ: TOCA), and Kezar Life Sciences (NASDAQ:KZR). Previous public company board service includes eleven years with Seattle Genetics, seven years with VaxGen, (vaccines/biodefense) and Aurinia (previously Isotechnika), based in Canada. He also serves or has served on private biotech company boards including Atreca, Applied Therapeutics, Immune Design, (acquired by Merck in 2019), Rain Therapeutics, CERUS Endovascular, Caprion Proteomics, (sold in July 2012) and ViroChem Pharma, which was purchased by Vertex Pharmaceuticals, for $400 million in 2009. Franklin has led multiple M&A analyses resulting in >$3 billion in transaction value.
Franklin started his consulting practice in 2003 after leaving J. P. Morgan Securities, Inc. as head of biotechnology equity research. His clients were exclusively biotechnology industry participants including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies. Assignments included business development, strategic advisory/financings, partnering and royalty acquisitions. Some of his past mandates include Stemcentrx, PDL BioPharma, Inc., Intra-Cellular Therapeutics, Serono, Merck KGaA, Threshold Pharmaceuticals, Valeant (formerly Biovail), Kleiner Perkins Caufield & Byers.
As a senior portfolio manager on the buy-side, Franklin worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from 2007 through June 2008. He reduced his consulting practice commitment during his full time employment with Sectoral Asset Management.
Franklin spent twelve years in sell-side equity research, most recently as Managing Director, U.S. Equity Research, J. P. Morgan Securities, Inc., from May 1998 to March 2003. During his five years at J. P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. Most of these transactions were lead-managed and book-run by the J. P. Morgan Biotech Team. He was associated with several notable financings in the biotechnology sector including the Genentech IPO, then the largest biotechnology IPO financing ever executed, the first large Celgene Corporation financings as well as several large-cap biotechnology companies in their rapid growth phase. His team covered 26 publicly-traded biotechnology companies. Franklin began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst.
Institutional Investor Magazine ranked Franklin #3 on J. P. Morgan’s All-Star Research Team. The Wall Street Journal selected him as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2000, he became a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine.
Franklin received his MBA from Harvard Business School in 1975; Johns Hopkins University conferred both his MA and AB degrees in 1971 and 1972, respectively.
Mark BonyhadiSenior Advisor
Mark Bonyhadi, PhD is a Senior Advisor at Qiming Venture Partners USA, based in Seattle, WA. Prior to joining Qiming USA in December of 2018, Mark held positions of Vice President of Research, Head of Academic Affairs, and Vice President of Process Research Sciences from 2013-2018 at Juno Therapeutics (acquired by Celgene Corporation).
From 2006-2013, Mark was Director of Global Business Development for Cell Therapy at Invitrogen, which was merged with Applied BioSystems, to create Life Technologies, which subsequently was acquired by Thermo-Fisher. Mark was responsible for identifying and implementing business opportunities aligned with the Lifetech/Invitrogen/Thermo cellular medicine portfolio, participating and leading in the launch of the Cell Therapy Systems (CTS™) product line optimized for cell therapy applications, as well as working with academia and industry to accelerate the development of novel cell and/or gene-based therapies.
From 1997-2005, Mark served as Director and later Vice President of Research at Xycte Therapies, a public Seattle-based T cell therapy company treating cancer, infectious disease and autoimmunity. Before heading to Xcyte, Mark spent from 1990-1997 working his way up to a Senior Scientist level at SyStemix, a public Palo Alto-based biotech company developing hematopoietic stem cell based therapies for treating cancer, as well as gene-therapy approaches for treating HIV infection. The latter was a collaborative effort with Sandoz, which later merged with Ciba Geigy to become Novartis.
Mark did his Postdoctoral training at SyStemix with Dr. Mike McCune and Dr. Hideto Kaneshima studying HIV pathogenesis in the SCID-hu mouse model. Mark is a former Chair and current member of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (ASGCT).
Mark received a B.A. from Reed College, Portland, OR and a PhD from UC Berkeley in the lab of James P. Allison, where he studied T cell immunology. Since graduating from UC Berkeley, Mark has been focused on the development of commercially viable approaches for bringing cell therapies, gene-modified cell therapies, and regenerative medicine from the bench, to the clinic, and into commercial use over the past three decades.
Mark currently lives in Seattle, WA.
Geoffrey DuykSenior Advisor
Dr. Duyk is a Partner of Circularis Partners, an investment firm focused on supporting technology-enabled companies that advance the circular economy, promote sustainability, and enhance resource efficiency. Circularis is a sub-advisor to the TPG Alternative & Renewable Technologies (ART) fund. Prior to Circularis, Dr. Duyk was the Managing Director and Partner of TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology from 2004 to 2017.
Prior to joining TPG, Dr. Duyk served on the Board of Directors and was President of R&D at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center.
Dr. Duyk currently serves on the Board of Directors of Amyris (Nasdaq: AMRS); Anuvia Plant Nutrients; Concentric; and Regen. He is a trustee of Case Western Reserve University where he Chairs the finance committee and is a member of the executive committee. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he Chairs the R&D committee. He previously served on the Board of Directors of the American Society of Human Genetics (ASHG) where he is currently a member of the organization’s finance committee and Chairs the investment committee. Dr. Duyk is a member of the Life Sciences Advisory Board of Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Lab (DOE). Previously, he served as a member of the SAB for Bayer CropSciences, Jackson Labs, as well as numerous NIH advisory committees.
Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from HHMI. He is a Fellow of the American Association for the Advancement of Science.
Scott MyersSenior Advisor
Scott Myers most recently served as President, Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (Nasdaq: AMAG) a biopharmaceutical company prior to its acquisition by Covis Pharma Holdings Sarl in the Fall of 2020.
Previously, he was Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer. Rainier partnered its asset with Fusion Pharma (Nasdaq: FSPM) in the Spring of 2020.
Prior to joining Rainier, Mr. Myers was Chief Executive Officer, President and Director of Cascadian Therapeutics (Nasdaq: CASC) until it was acquired by Seattle Genetics (Nasdaq: SGEN) in March 2018. He was also CEO of Aerocrine AB (OMX Nasdaq: AERO), a Swedish Medtech company from September 2011 until its acquisition by Circassia, PLC in July of 2015. He has held senior commercial operations, general management and information management positions for UCB SA, a Belgium-based biopharmaceutical company, and Johnson & Johnson.
Scott is also Chairman of the Board for Harpoon Therapeutics (Nasdaq: HARP), Dynavax (Nasdaq: DVAX), and Sensorion (Paris: ALSEN) along with an Independent Director for SelectaBiosciences (Nasdaq: SELB). He was also previously on the board for Trillium Therapeutics (Nasdaq: TRIL) prior to acquisition by Pfizer.
Myers earned his B.A. in biology from Northwestern University and his M.B.A. from the University of Chicago’s Graduate School of Business (Booth).
Robert HeadleySenior Advisor
Robert Headley is a partner at Ignition. He joined the firm in 2000. Robert has led fundraising efforts for more than $2 billion in capital commitments across seven Ignition and affiliated funds.
Robert previously served as a director for Enclarity (acquired by LexisNexis), Extend America (acquired by Spring) and several other Ignition portfolio companies.
Prior to joining Ignition, Robert spent seven years at Starbucks Coffee Company, most recently as vice president, finance & treasurer. In that role, he managed Starbucks investor relations, corporate development, Treasury, business planning & analysis, and profit improvement functions.
Before Starbucks, Robert spent three years in the principal investment area and investment banking division of Goldman Sachs in New York and Sydney, Australia.
Robert holds an MS and BS degree with distinction in industrial engineering from Stanford University.
Ryan BakerChief Financial Officer
Ryan joined Qiming Venture Partners USA as the CFO in early 2020, however, he has worked closely with the Qiming Global team dating back to 2011. Ryan also serves as the Administrative Partner & CFO for Ignition Partners, which has provided top tier finance and back-office support to Qiming since its inception. As the Qiming USA CFO, Ryan oversees the finance operations and is responsible for managing the firm’s financial, operational, and administrative activities. He continues to support and work closely with the Qiming Global team as well.
Prior to joining Ignition in 2011, Ryan spent over 7 years with Vulcan, Inc., where he was responsible for the investment accounting and related fund administration for Vulcan Capital’s multi-billion dollar investment portfolio, including early-stage venture capital, public securities, larger-scale private equity, and other alternative asset classes. Prior to Vulcan, Ryan spent 4 years in the audit practice of Ernst & Young, including a one-year rotation at the firm’s national headquarters in New York City.
Ryan is a CPA and earned a B.B.A. in Accounting from the University of Notre Dame.
Holly SchlichtingExecutive Assistant
Holly joined Qiming Venture Partners USA team in early 2021 and is based in the Cambridge, Ma Office.
Holly brings over 30 years of office experience in administration and operations management. Prior to joining the firm, she worked in the biotech/pharma sector where she helped companies grow from early to late-stage operations with experience in IPO’s & acquisitions. Holly currently serves as the administrator for the CEO-Forum that was started at the onset of Covid-19 to help CEOs of the Biotech industry navigate the response and corporate decision-making pertaining to COVID-19.
Prior to joining the Biotech industry, Holly worked for 20 years for Stark Carpet’s Boston showroom located in the Innovation and Design Building in Boston where she handled office operations, sales & service of high-end interior installations.
When not in the office you can find Holly kayaking off the shores of her hometown, volunteering for various charities in her community and spending time with her family.
Laurel BrakusExecutive Assistant
Laurel joined Qiming Venture Partners in January 2021 as an Executive Assistant. Laurel brings a diverse background of over 20 years of experience in investor relations, management, marketing and event planning to the Qiming team.
Prior to Qiming, Laurel spent 14 years as an Executive Assistant at Ignition Partners, a venture capital firm based in Bellevue WA. Laurel dedicated much of her time towards investor relations, event planning and administrative support to various senior partners. She was primarily responsible for organizing Ignition’s LP Annual Meetings held in Seattle and San Francisco, managing quarterly LP and Advisory Committee Update Calls, coordinating extensive travel in relation to fundraising roadshows and investor meetings and also acted as a point of contact to investors. Laurel coordinated several marketing events with co-hosts such as: Amazon, Microsoft and other technology and venture capital firms.
Laurel studied performing arts in Portland, OR and Los Angeles, CA and holds an HR Certificate from the University of Washington.
Laurel is passionate about health and wellness, enjoys yoga, and packing up her classic truck and exploring the endless beauty of the Pacific Northwest.
Emma AndersonExecutive Assistant & Operations
Emma joined Qiming Venture Partners in September 2021 as an Executive Assistant and is based in the Brisbane, CA office. She was born and raised in the Bay Area and grew up around the Venture Captial/Tech world.
Emma comes to Qiming with over 7 years of office and administrative experience. She has worked a majority of her career in the Venture space, helping with office operations and executive support. She has spent the last few years working for a global VC firm that focused on rapidly growing tech firms located around the world.
Prior to that she’s lived and worked in London and Santa Barbara as well as spent some time traveling.
When Emma is not in the office you can find her in the gym, traveling or spending time with her family.